A previously healthy 26-month-old boy is hospitalized with what appears to be a routine viral infection. Within days, he is diagnosed with Hemophagocytic Lymphohistiocytosis (HLH), a rare and often fatal immune disorder. Despite advanced clinical intervention, he died of multi-organ failure just 44 days later.

The tragedy isn't just the disease's severity but also that mutations in the PRF1 gene, a key genetic driver of HLH, have been known for over 20 years¹. Despite this, infant mortality remains as high as 40%–80%, depending on treatment timing and access to transplantation². The gap between genetic discovery and effective treatment marks a major failure in genomic medicine.

CRISPR has given unprecedented power to identify and target mutations, but the development of therapies is slow. The main issue is the one-disease-at-a-time approach, which requires building each therapy from scratch.

For rapidly progressing pediatric disorders, tailored innovation is not enough. The next era of CRISPR medicine will depend on scalable, reusable platforms that

From One-Off Therapies to Scalable Platforms

Scientists, therapy developers and regulators face a key challenge: delivering personalized cures within patient-survivable timelines amid the gap between concept and clinic. Supported by life sciences partners such as Danaher, innovative technologies are accelerating CRISPR therapies from the lab to the clinic. A collaboration between Acuitas Therapeutics, IDT and Aldevron delivered a personalized CRISPR therapy to an infant with neonatal-onset urea cycle disorder in six months.³

But a critical question remains: what happens when the next disease appears?

There are over 500 identified inborn errors of immunity (IEIs) that collectively affect more than 110,000 people.⁴ Under the current paradigm, each new indication requires a personalized CRISPR therapy.

Addressing every IEI in this way is akin to shipping cargo between New York and San Francisco via Cape Horn, one box at a time. A far more effective route would be the equivalent of the Panama Canal: a system designed for scale, where the infrastructure remains constant and only the payload changes.

This is the essence of a platform approach: a shared CRISPR infrastructure designed to support multiple therapeutic execution modes, from standardized gene addition to mutation-specific editing.

A Platform Workflow for CRISPR Therapeutics

In the traditional gene therapy paradigm, treating a patient with a unique mutation requires designing a custom system from scratch, including a specific guide RNA and repair template. This process can take years, making it poorly suited to rapidly progressing diseases.

A platform approach redefines this workflow by separating what is fixed from what is variable. Instead of targeting different loci per patient, the system is anchored to a pre-validated genomic landing site. This enables the reuse of a standardized CRISPR backbone comprising Cas9, a delivery system and a manufacturing workflow across indications.

Within this framework, the only variable is the therapeutic DNA payload encoding the functional gene sequence. This plug-and-play architecture shifts development toward rapid production and validation of new payloads or, where required, iterative design and screening of guide RNAs within a shared manufacturing and validation framework.

Anchoring the system to a pre-validated genomic landing site allows safety and performance data to focus on a single, well-characterized edit. While each payload still needs validation, the core editing mechanism can be reused across indications, reducing redundancy in preclinical and regulatory workflows. This enables a more flexible regulatory model that evaluates the payload instead of revalidating the entire system.

By standardizing the “how,” the field can finally focus on the “what”, delivering the right genetic instruction at the right time, before the window for intervention closes.

Bypassing the Mutation: A Gene Augmentation Strategy

A central question in the platform approach remains: How can we cure a disease if the “broken” gene is still present in the cell? The answer lies in functional restoration rather than direct correction.

In many rare pediatric conditions, disease arises from loss-of-function mutations leading to insufficient production of a critical protein.4 Instead of repairing the defective locus, a platform strategy introduces a functional copy of the gene into a standardized genomic landing site. This gene augmentation strategy restores protein levels above the therapeutic threshold while bypassing the impact of the endogenous mutation.

This model suits loss-of-function disorders best. In complex monoallelic disorders, allelic differences influence response and dominant-negative and gain-of-function mechanisms further complicate the picture. Platform workflows can test multiple candidates simultaneously to find the best strategy for a specific genetic context.

Importantly, both execution modes still share a common foundation: standardized delivery systems, manufacturing pipelines, analytical assays and regulatory frameworks. Together, these dual tracks define a unified platform logic, one that preserves industrial scalability while accommodating the diversity of IEI-driven diseases.

From Fragmented Workflows to Integrated Execution

The full potential of a CRISPR platform emerges [ED1] only when discovery, validation and manufacturing operate as a coordinated system rather than isolated steps.

One of the first challenges is practical and ethical: limited access to patient cells. In fragile pediatric cases, repeated invasive sampling is not feasible. Employing a digital-to-biological twin strategy can help solve this challenge. By beginning with healthy, standardized Hematopoietic Stem and Progenitor Cells (HSPCs) from a donor bank, patient-specific mutations can be introduced via precision base editing, creating a controlled system that recapitulates the disease. This surrogate model can enable extensive testing and optimization without placing an additional burden on the patient.

The main bottleneck shifts to workflow speed. Finding a viable edit is just the first step; developers must also choose the best guide, create CRISPR components, optimize delivery and validate function before confirming therapy. Typically, these steps are disjointed, delaying development by months. When integrated into a single iterative loop within a CRISPR platform, these stages can be shortened to days.

This model, illustrated by integrated ecosystems such as Danaher’s, replaces slow, custom development with a coordinated execution engine better aligned with the urgency of rare pediatric diseases.

The CRISPR Cookbook: Toward a Scalable Model for Genomic Medicine

Platform-based CRISPR development is prompting a redefinition of what constitutes a “new” therapy in regulatory assessment. When core components and manufacturing processes are held constant across indications, full-system re-evaluation becomes increasingly redundant, shifting attention to the disease-specific genetic payload.

The long-term vision is to create a “CRISPR Cookbook”: a validated, regulatory framework for scalable genetic therapies. Using Danaher’s integrated solutions, the field moves toward standardizing cure ingredients. When a child with a novel mutation appears, the "Cookbook” ensures the recipe is mostly defined, with only disease-specific elements needing validation.

This approach has global implications. A platform with standardized components can be deployed widely in clinical settings, increasing access to advanced therapies. Instead of being limited to specialized centers, CRISPR treatments could be implemented through adaptable local workflows, making precision medicine more accessible to patients who need it.

References

1. Stepp SE, Dufourcq-Lagelouse R, Deist FoL, Bhawan S, Certain S, Mathew PA, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999;286(5446):1957-1959.
2. Alfaraidi AT, Alqarni AA, Aqeel MT, Albalawi TA, Hejazi AS. Familial hemophagocytic lymphohistiocytosis secondary to PRF1 mutation. Case Rep Hematol 2021;2021(1):7213939.
3. Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, et al. Patient-specific in vivo gene editing to treat a rare genetic disease. NEJM 2025;392(22):2235-2243.
4. Poli MC, Aksentijevich I, Bousfiha AA, Cunningham-Rundles C, Hambleton S, Klein C, et al. Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. JHI 2025;1(1):e20250003.